Inactive Instrument

Insiders ALKERMES Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
- ^USD	-

May. 02	UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating	MT
May. 01	Alkermes's Q1 Earnings, Revenue Grow But Miss Street View	MT

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alkermes Insider Sold Shares Worth $292,740, According to a Recent SEC Filing	Mar. 19	MT
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors	Mar. 07	CI
Alkermes plc Announces Executive Changes	Feb. 05	CI
Alkermes plc Announces Changes to its Board	Dec. 08	CI
Biogen shareholders back Susan Langer as director	23-06-26	RE
ISS recommends one of Sarissa's three nominees for Alkermes board	23-06-20	RE
ISS backs election of Langer to replace former Biogen director Denner	23-06-15	RE
Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes	23-06-13	RE
Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes	23-06-13	RE
Alkermes Names Caroline Loew Chief Executive Officer Designate of Planned Oncology Company	23-06-02	MT
Insider Sell: Alkermes	23-05-10	MT
Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process	23-05-08	PR
Insider Buy: Alkermes	22-11-16	MT
Insider Sell: Alkermes	22-06-21	MT
Alkermes plc Announces Management Changes	22-05-26	CI
Insider Sell: Alkermes	22-05-20	MT
Insider Sell: Alkermes	22-05-03	MT
Insider Sell: Alkermes	22-05-03	MT
Insider Sell: Alkermes	22-04-19	MT
Sarissa Capital Management LP Nominates Candidates to the Board of Alkermes plc	22-01-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer